Bio Startup Tisento Launches With $81M and a Brain-Penetrating Drug in the Clinic
A Phase 2b-ready Cyclerion Therapeutics drug candidate for a rare mitochondrial disease gets new life under a new startup led by a familiar face. Tisento Therapeutics acquired the Cyclerion drug and is backed by a Series A round financing.